Pembrolizumab Induces Antitumor Activity in Previously Untreated HCC
January 18th 2021Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.
Second-Line Pembrolizumab Has Maintained Survival Benefit in Advanced HCC
January 18th 2021January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.
Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs
January 17th 2021January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.
Infigratinib Shows Promising Anticancer Activity in Chemo-Refractory, FGFR2+ Cholangiocarcinoma
January 17, 2021 - Infigratinib was found to be associated with encouraging clinical activity with a manageable safety profile in patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.
Ivosidenib Induces OS Benefit in Advanced IDH1+ Cholangiocarcinoma
January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.
TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy
January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.
Addition of Pembrolizumab to Chemo Does Not Negatively Impact QoL in Patients With Esophageal Cancer
January 16th 2021January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.
Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC
January 16th 2021January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types
January 15th 2021The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers
Adjuvant S-1/Docetaxel Combo Shows Survival Improvement in Stage III Gastric Cancer
January 15, 2021 - Combination treatment with adjuvant S-1 and docetaxel led to an estimated 29% reduction in the risk of relapse compared with S-1 alone in patients with stage III gastric cancer.
Anlotinib Induces PFS Benefit in RAS/BRAF Wildtype+ mCRC
January 15th 2021January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.
Nivolumab Improves Quality of Life in Patients with Esophageal/Gastroesophageal Cancer
January 15th 2021January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.
Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell Carcinoma
January 15th 2021January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.
Pembrolizumab/Lanreotide Combo Confers Antitumor Activity in GEP-NETs
January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.
Pembrolizumab Plus Capecitabine/Bevacizumab Shows Favorable Tolerability in MSS mCRC
January 15th 2021January 15, 2021 - Pembrolizumab (Keytruda) in combination with capecitabine and bevacizumab (Avastin) was found to show encouraging tolerability when used in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to data from a phase 2 trial (NCT03396926) presented during the 2020 Gastrointestinal Cancers Symposium.